University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aleman, Tomas
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
NCT05616793: Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)

Recruiting
1/2
15
US
AAV8.hLCA5
Opus Genetics, Inc, University of Pennsylvania
LCA5
12/24
01/28
LIGHTHOUSE, NCT05878860: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Recruiting
1/2
21
US
ATSN-201
Atsena Therapeutics Inc.
X-linked Retinoschisis
10/25
10/29
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Recruiting
N/A
1500
Europe, Canada, US, RoW
Jaeb Center for Health Research, Foundation Fighting Blindness
Inherited Retinal Degeneration, Retinitis Pigmentosa
12/28
12/28
Pearson, Denise
NCT03969992: A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

Completed
2
261
Canada, US
AeroFact, SF-RI 1, nCPAP
Aerogen Pharma Limited
Respiratory Distress Syndrome in Premature Infant
08/23
08/24

Download Options